Among patients with resected metastatic melanoma stages III and IV, a shorter treatment duration with adjuvant anti-PD1 antibodies is not associated with worse outcomes, according to study results published in the Journal of the European Academy of Dermatology and Venereology.
2025
Dr Pavlick on RP1 Plus Nivolumab in PD-1 Inhibitor–Pretreated Melanoma
Anna C. Pavlick, BSN, MSc, DO, MBA, a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian, discussed key findings from the phase 2 IGNYTE trial (NCT03767348) investigating the efficacy and safety of RP1 plus nivolumab (Opdivo) in patients with melanoma who had progressed on prior PD-1–directed therapy.
BBC presenter’s melanoma campaign ‘saved our lives
A couple has credited a BBC presenter’s campaign to raise awareness of skin cancer risks with saving their lives.
Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma
HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit profile compared with best alternative care (BAC), according to a study published online April 7 in the Annals of Surgical Oncology.